Taurocholic Acid: A Comprehensive Reference
1. Identity: Chemical Names, Natural Sources, and Commercial Forms
1.1 Nomenclature and Chemical Identity
Taurocholic acid, known also as cholaic acid, cholyltaurine, or acidum cholatauricum, is a deliquescent yellowish crystalline bile acid involved in the emulsification of fats. It is a bile acid conjugate formed by the amidation of cholic acid with taurine, serving as a key component of bile in mammals. It has the molecular formula C26H45NO7S and a molecular weight of 515.7 g/mol, typically occurring as a white to off-white crystalline powder that decomposes around 125 °C and exhibits good solubility in water.
By formal chemical definition, taurocholic acid is a bile acid C26H45NO7S derived from cholic acid and taurine and occurring as the sodium salt in the bile especially of carnivores. In its sodium salt form (sodium taurocholate, CAS No. 145-42-6), it is a deliquescent acid occurring in the bile of humans, the ox, and various carnivores. The first recorded use of the term "taurocholic acid" in the scientific literature dates to 1857.
1.2 Natural Sources and Occurrence
Bile acids, also known as steroid acids, are amphiphilic water-soluble molecules that are mainly synthesized by the liver (primary forms) and by bacterial transformation in the colon (secondary forms). They are usually found as conjugates with taurine or glycine in the bile of mammals and vertebrates.
In humans, taurocholic acid and glycocholic acid (derivatives of cholic acid) and taurochenodeoxycholic acid and glycochenodeoxycholic acid (derivatives of chenodeoxycholic acid) are the major bile salts. The salts of their 7-alpha-dehydroxylated derivatives, deoxycholic acid and lithocholic acid, are also found, with derivatives of cholic, chenodeoxycholic and deoxycholic acids accounting for over 90% of human biliary bile acids.
The bile acid pool contains about 2.5–5 g of bile acids, which are conjugated either with taurine or glycine to form water-soluble bile salts. Bile salts have different abundances in bile, with glycoconjugates making up about 70% and tauroconjugates accounting for 30% of human bile salt mixtures.
Its sodium salt is the chief ingredient of the bile of carnivorous animals. For commercial use, taurocholic acid is manufactured from cattle bile, a byproduct of the meat-processing industry.
1.3 Common Forms and Preparations
Taurocholic acid is available in several forms for research and medical use:
- Free acid form: A white to off-white crystalline powder with good solubility in water.
- Sodium taurocholate: Sodium 2-[(4R)-4-[(1R,3aS,3bR,4R,5aS,7R,9aS,9bS,11S,11aR)-4,7,11-trihydroxy-9a,11a-dimethyl-hexadecahydro-1H-cyclopenta[a]phenanthren-1-yl]pentanamido]ethane-1-sulfonate, the pharmacologically active salt form used in clinical and experimental settings.
- Cholagogue/choleretic preparations: In medical use, it is administered as a cholagogue and choleretic.
- Bile extract preparations: Historically, bile extracts containing taurocholic acid have been used in traditional medicine for digestive support.
2. Biosynthesis: How the Body Produces Taurocholic Acid
Taurocholic acid is synthesized in hepatocytes through the classical, or neutral, pathway of bile acid biosynthesis, which begins with the conversion of cholesterol to 7α-hydroxycholesterol by the rate-limiting enzyme cholesterol 7α-hydroxylase (CYP7A1). This pathway predominates in humans and leads to the formation of cholic acid as the primary bile acid precursor for taurocholic acid. Subsequent enzymatic steps involve multiple hydroxylations and oxidations, culminating in the production of cholic acid, chemically known as 3α,7α,12α-trihydroxy-5β-cholan-24-oic acid.
Cholic acid is then activated by bile acid-CoA ligase (BACL), also referred to as bile acid-CoA synthetase, which conjugates it with coenzyme A to form cholyl-CoA. This activation occurs at the basolateral membrane of hepatocytes, with cholyl-CoA then shuttled to peroxisomes for the subsequent conjugation step.
The human liver is able to synthesize from cholesterol only primary bile acids such as chenodeoxycholic acid (CDCA) and cholic acid, which are further conjugated with glycine or taurine and secreted in bile in a form of taurocholic acid, glycocholic acid, glycochenodeoxycholic acid, and taurochenodeoxycholic acid. Further processing of primary bile acids is performed by gut bacteria and finally results in the formation of secondary bile acids.
Daily secretion of bile acids by the liver amounts to approximately 12 to 18 grams in adults. In man, the total bile acid pool (3–5 g) recirculates 6–10 times per day giving rise to a daily uptake of approximately 20–30 g of bile acids.
3. Traditional and Historical Use
For centuries, traditional Chinese medicine has valued animal bile for its use in pharmacological and clinical applications. Bile acids are natural products and fundamental components of bile.
Historically, bile extracts and bile acids have been used in traditional medicine, particularly in Chinese and European contexts, to support digestion and liver health. Early practitioners believed that taurocholic acid and related bile acids could dissolve gallstones, relieve constipation, and combat jaundice, making them valuable tools in the management of digestive and hepatic disorders.
Traditional Asian medicine recommended the use of vertebrate and invertebrate bile for patients with visual disorders.
It is important to note a distinction that runs through the historical use of bile-based preparations: the closest well-documented traditional use pertains primarily to bile from bear (which is rich in tauroursodeoxycholic acid, a related conjugated bile acid) and ox bile (rich in taurocholic acid). UDCA has been used for over a millennium in traditional Chinese medicine, and is a principal therapy for a number of gastrointestinal diseases including cholestasis. The broader category of bile acid-containing preparations was employed across cultures for digestive, hepatic, and ophthalmological complaints, though specific documentation isolating taurocholic acid as a discrete agent belongs to the modern pharmacological era, with the compound being chemically characterized in the nineteenth century.
4. Key Constituents and Active Compounds
Taurocholic acid is itself the active molecule; it is not a complex botanical extract. Its biological effects are intrinsic to its unique chemical structure: a steroidal bile acid backbone derived from cholesterol, conjugated via an amide bond to the sulfonated amino acid taurine.
Hydrolysis of taurocholic acid yields taurine. Taurine is a sulfur-containing amino acid that, once liberated by bacterial or enzymatic hydrolysis in the gut, participates in further metabolic reactions in the host and in microbial communities.
The purpose of conjugation (with taurine) is so that the bile acids can become water-soluble and thereby emulsify fats. The sulfonate group of the taurine moiety gives taurocholic acid a markedly lower pKa compared to unconjugated bile acids, meaning it remains ionized (and therefore soluble) even in the acidic environment of the upper small intestine, enabling effective micelle formation across a wider range of pH.
5. Mechanisms of Action
5.1 Lipid Emulsification and Micelle Formation
Bile salts are steroidal detergents, which form mixed micelles with lipids, fats, and/or cholesterol, and thus enable the digestion and absorption of fats and fat-soluble vitamins in the intestine.
Bile acids facilitate the emulsification and absorption of dietary lipids and fat-soluble vitamins in the small intestine. The absorption of lipid-soluble vitamins from the diet requires the detergent actions of bile acids. Bile acids are amphipathic sterols synthesized from cholesterol in the liver and secreted into the intestine, where, when present at high concentrations, they function to emulsify dietary lipids.
Taurocholic acid, as with all bile acids, acts as a detergent to solubilize fats for absorption and is itself absorbed.
5.2 Enterohepatic Circulation
As a major conjugated bile acid, taurocholic acid participates in the enterohepatic circulation, a highly efficient recycling process that conserves the bile acid pool in humans. The majority (~95%) of bile acids are efficiently reabsorbed in the ileum and returned to the liver, a process known as enterohepatic circulation, which ensures their efficient reuse but also creates a dynamic pool that can be influenced by dietary and microbial factors.
About 95% of bile acids, including taurocholic acid, are reabsorbed in the ileum via the apical sodium-dependent bile acid transporter (ASBT), facilitating active uptake into enterocytes. In the intestine, bile acids enter intestinal cells through the action of the apical sodium-dependent bile acid transporter (ASBT) and subsequently bind to the ileal bile acid binding protein (IBABP), facilitating their transport from the apical surface to the basolateral membrane. With the assistance of the organic solute transporter (OST) and organic anion transporting polypeptides (OATP), bile acids then enter the portal vein and are transported to the liver.
5.3 Nuclear Receptor Signaling: FXR
Recent evidence suggests that changes in microbiota composition directly affect the metabolism of bile salts. Next to their role in digestion of dietary fats, bile salts function as signaling molecules for bile salt receptors such as the Farnesoid X receptor (FXR) and G protein-coupled bile acid receptor (TGR5).
Bile acids in hepatocytes, ileal enterocytes, and colonic L cells bind to FXR and activate the FXR-RXR heterodimer complex, resulting in the transcription of target genes. Within liver cells, bile acids activate FXR receptors, which in turn promote the expression of small hetero-dimer partner (SHP), resulting in the inhibition of bile acid synthesis enzymes. Additionally, bile acids that enter intestinal cells activate FXR, leading to the secretion of FGF15/19, which subsequently travels to the liver via the portal vein to inhibit CYP7A1, thereby reducing bile acid synthesis.
FXR exerts anti-inflammatory effects by suppressing NF-κB signaling and cytokine production, whereas TGR5 primarily regulates NLRP3 inflammasome activation.
5.4 G Protein-Coupled Receptor Signaling: TGR5
Taurocholic acid is a potent TGR5 ligand, and in dogs, colonic perfusion with TCA induces PYY secretion.
TGR5 activation in colonic L cells increases synthesis and release of GLP-1. TGR5 in skeletal muscle and brown adipose tissue increases energy expenditure by promoting the conversion of inactive thyroxine (T4) into active thyroid hormone (T3). Ligand binding of TGR5, which is a transmembrane receptor, leads to increased levels of intracellular cyclic AMP (cAMP), and this triggers further downstream signaling events.
In primary murine intestinal cultures, taurocholic acid (100 or 1000 µmol/L) dose-dependently increased GLP-1 release. This finding, while preclinical, links taurocholic acid's TGR5 agonism to gut hormone secretion relevant to glucose homeostasis.
5.5 Cholagogue and Choleretic Actions
Taurocholic acid is used as a cholagogue and choleretic (a bile purging agent). As a cholagogue, it promotes the contraction of the gallbladder and flow of bile into the duodenum. As a choleretic, it stimulates the liver to increase bile production. These actions are its primary historically recognized pharmacological activities.
5.6 Cholesterol Metabolism
Bile acids have other functions, including eliminating cholesterol from the body, driving the flow of bile to eliminate certain catabolites (including bilirubin), emulsifying fat-soluble vitamins to enable their absorption, and aiding in motility and the reduction of the bacteria flora found in the small intestine and biliary tract.
5.7 Interaction with the Endocannabinoid System
Among the protein targets of bile acids is the membrane enzyme N-acyl phosphatidylethanolamine-specific phospholipase D (NAPE-PLD) of the endocannabinoid system. Bile acids are essential cofactors for the biogenesis of lipid signaling amides (e.g., anandamide, palmitoylethanolamide, oleoylethanolamide) mediated by NAPE-PLD. These lipid molecules (e.g., the endogenous cannabinoid anandamide) have important roles in several physiological pathways including stress and pain responses, appetite, and lifespan. NAPE-PLD thus facilitates crosstalk between bile acid signals and lipid amide signals.
6. Body Systems and Health Areas Associated with Taurocholic Acid
6.1 Digestive System and Hepatobiliary Health
The most fundamental and unambiguous role of taurocholic acid is in the gastrointestinal tract. In the gastrointestinal tract, taurocholic acid plays a crucial role in lipid digestion by acting as a detergent-like surfactant that emulsifies fats and phospholipids, enabling their breakdown by lipases and subsequent absorption in the small intestine.
In terms of supporting the gallbladder, taurocholic acid's primary function is as a component of bile, which aids in digestion. There is some scientific evidence, mostly from animal studies and biochemical research, showing that supplementation with bile acids (including taurocholic acid) can influence bile composition and flow. This may, in theory, support gallbladder function and reduce the risk of gallstone formation by keeping cholesterol in solution.
Bile acids including cholic acid, its taurine conjugate (taurocholate), and lithocholic acid can cause cholestasis and hepatocellular damage when present in excess. This injury is accompanied by alterations in the expression of hepatobiliary transporters.
6.2 Gut Microbiome
Recent evidence suggests that changes in microbiota composition directly affect the metabolism of bile salts. Next to their role in digestion of dietary fats, bile salts function as signaling molecules for bile salt receptors such as the Farnesoid X receptor (FXR) and G protein-coupled bile acid receptor (TGR5). Complementary to their role in metabolism, FXR and TGR5 are shown to play a role in intestinal homeostasis and immune regulation.
Deconjugation increases the hydrophobicity and potential toxicity of bile acids, as unconjugated forms like cholic acid are more detergent-like and can disrupt bacterial membranes, thereby shaping the composition of the gut microbiota. The released taurine serves as a nutrient source, promoting the growth of taurine-utilizing bacteria and supporting overall microbial diversity.
6.3 Cardiometabolic Health
Bile acids activate both the nuclear receptor FXR and the membrane receptor TGR5, which in turn influence glucose and lipid metabolism, modulate inflammatory processes, and affect vascular functions. These signaling pathways collectively link metabolic and immune networks within the cardio-metabolic axis.
6.4 Gut–Brain Axis and Neurological Health
The gut–brain axis is a bidirectional communication network in which gut microbiota and their metabolites influence central nervous system (CNS) function. Among these metabolites, bile acids have emerged as key signaling molecules that modulate metabolic and neuroendocrine pathways. Microbiota-mediated modifications of bile acid composition affect receptors such as FXR and TGR5, thereby influencing neuronal activity, appetite control, glucose metabolism, and energy balance.
7. Scientific Evidence by Area of Use
7.1 Lipid Absorption and Fat-Soluble Vitamin Absorption
The role of taurocholic acid in lipid and fat-soluble vitamin absorption is mechanistically established and widely described in physiological and biochemical literature. This is the area of strongest and most consistent evidence.
The absorption of lipid-soluble vitamins from the diet requires the detergent actions of bile acids. Bile acids are amphipathic sterols synthesized from cholesterol in the liver and secreted into the intestine, where, when present at high concentrations, they function to emulsify dietary lipids. This physiology is foundational and not disputed in the literature.
Evidence strength: Mechanistic and physiological evidence is robust and well-replicated. Controlled human clinical trials specifically isolating taurocholic acid as an exogenous supplement for this purpose are limited; most evidence is derived from physiology studies and indirect data from bile acid deficiency states.
7.2 Colorectal Cancer Risk
This is an area with significant, though complex and primarily associative, evidence. TCA and its microbial metabolites are implicated in colorectal cancer (CRC) risk through diet-dependent mechanisms.
In a large prospective study (involving 569 incident colon cancer cases and 569 matched controls) it was found that prediagnostic concentrations of circulating taurocholic acid, as well as six other bile acids, were statistically significantly associated with increased colon cancer risk.
Recent evidence has linked a high fat and animal protein diet and microbial metabolism of host bile acids as environmental risk factors for CRC development. Researchers hypothesize that the primary bile salt taurocholic acid (TCA) is a key, diet-controlled metabolite whose use by bacteria yields a carcinogen and tumor-promoter, respectively. The work is motivated by published data indicating hydrogen sulfide (H2S) and secondary bile acid production by colonic bacteria serve as environmental insults contributing to CRC risk.
The mechanistic basis for this association is increasingly well characterized: the taurine provided by bacterial deconjugation of TCA is used as a substrate by B. wadsworthia for anaerobic respiration generating genotoxic H2S. Once deconjugated, free primary bile acids are further metabolized by colonic bacteria to genotoxic and pro-inflammatory secondary bile acids. Specifically, the production of the secondary bile acid DCA acts as a tumor promoter by causing membrane perturbations leading to the release of arachidonic acid, which is converted by the enzymes COX-2 and lipoxygenase to pro-inflammatory and pro-angiogenic prostaglandins, and reactive oxygen species which damage DNA and inhibit DNA repair enzymes.
Specifically, TCA is hypothesized to be a key diet-controlled metabolite whose metabolism by Bilophila wadsworthia (or related taxa capable of converting taurine to H2S) and Clostridium scindens (or related taxa capable of converting cholic acid to deoxycholic acid) yields a carcinogen and a tumor-promoter, respectively.
A prospective, randomized, crossover feeding trial was designed to test this hypothesis directly: the trial examines two microbial mechanisms by which an animal-based diet may support the growth of TCA metabolizing bacteria. Each subject receives two diets in a crossover design—an animal-based diet, rich in taurine and saturated fat, and a plant-based diet, low in taurine and saturated fat. A mediation model is used to determine the extent to which diet and mucosal markers of CRC risk and DNA damage are explained by colonic bacteria and their functions.
In mice without disruption of relevant genes, a diet high in saturated (milk-derived) fat promoted expansion of the immunogenic sulfite-reducing pathobiont Bilophila wadsworthia, a member of the Deltaproteobacteria. The Bilophila wadsworthia expansion resulted from a high-fat diet-induced shift in hepatic conjugation of bile acids, from glycocholic to taurocholic acid, which helps solubilize the more hydrophobic diet.
Evidence strength: The association between elevated circulating TCA and colon cancer risk is from a single large prospective study. Mechanistic evidence from animal and in vitro studies is substantial, but direct human interventional trial data specifically targeting TCA as an isolated variable are limited. The overall picture is compelling but causal attribution remains under active investigation.
7.3 Hepatic Lipid Accumulation (Preclinical)
Dietary bile acid (BA) supplementation can notably ameliorate fatty liver disease caused by high dietary lipids, but the mechanism behind this is poorly understood. Research into TCA (taurocholic acid sodium) aimed to reduce hepatic lipid accumulation via the regulation of bile acid metabolism. In a dietary supplementation study in juvenile hybrid grouper, the TCA diet (about 900 mg kg−1) significantly reduced lipid accumulation in the liver, thus improving liver health.
Evidence strength: These findings are from animal (fish) models. No equivalent human clinical trials have been conducted for this specific indication.
7.4 GLP-1 Secretion and Metabolic Regulation
TGR5 activation by taurocholic acid is known to stimulate the release of glucagon-like peptide-1 (GLP-1) from intestinal L cells. In primary murine intestinal cultures, taurocholic acid (100 or 1000 µmol/L) dose-dependently increased GLP-1 release. Taurocholic acid is a potent TGR5 ligand, and in dogs, colonic perfusion with TCA induces PYY secretion.
Evidence strength: Preclinical (in vitro and animal) evidence only. Direct human clinical data on GLP-1 stimulation by exogenous taurocholic acid supplementation are lacking.
7.5 Inflammatory Bowel Disease and Intestinal Homeostasis
Research has shown that patients with Crohn's disease have a smaller bile acid pool, and the ratio of glycine to taurine complexes significantly increases. The decrease in bile acid pool size is related to disease activity. The deficiency of secondary bile acids produced by gut microbiota can promote intestinal inflammation, while certain secondary bile acids can alleviate inflammation in mouse colitis models.
Dysregulated bile acid signaling, driven by microbial dysbiosis, exacerbates inflammatory diseases like non-alcoholic fatty liver disease (NAFLD) and inflammatory bowel disease (IBD).
Evidence strength: Predominantly mechanistic and animal model data. Human clinical trials specifically testing taurocholic acid supplementation in IBD have not been reported. The role of the broader bile acid pool in IBD is an active area of research.
7.6 Gut–Brain Axis and Neurological Function
Emerging evidence suggests that bile acid signaling constitutes a crucial interface linking gut microbial activity to CNS function. Microbiota-driven transformations of bile acids modulate receptor activation and downstream signaling cascades that can impact neuronal activity, hypothalamic regulation of appetite, and even cognitive processes. Understanding the dynamic relationship between microbial bile acid metabolism and neural signaling provides a framework for novel therapeutic interventions targeting the gut–brain axis in metabolic and neurodegenerative diseases.
Evidence strength: Emerging, primarily preclinical. Most clinical neuroscience evidence in the bile acid domain pertains to TUDCA (tauroursodeoxycholic acid), a distinct but structurally related conjugated bile acid.
8. Dosage Forms and Reported Dosages
There is no established standard supplemental dose of taurocholic acid for humans, and it is not approved by the FDA or EMA as a drug in isolation for any therapeutic indication. Dosage information that does exist comes from investigational and experimental contexts:
- Preclinical animal (dietary supplementation): A TCA diet of approximately 900 mg/kg was used in fish studies and significantly reduced lipid accumulation in the liver.
- Preclinical animal (in vitro, GLP-1 release): Concentrations of 100 or 1000 µmol/L were used in primary murine intestinal cultures to study GLP-1 release.
- Preclinical animal (cardiotoxicity studies): The effect of taurocholate at 0.3 mM and 3 mM was studied on cultures of cardiomyocytes.
- Preclinical animal (maximum tolerated dose, intravenous): For taurocholate, tests indicated that 167 µmol/kg of body weight delivered intravenously was the maximum tolerated dosage in mice.
- Investigational pharmaceutical (oral administration): The median lethal dose of taurocholic acid in newborn rats is 380 mg/kg.
It is important to note that available human dosage data pertain largely to closely related bile acids used as drugs (e.g., ursodeoxycholic acid, cholic acid) rather than to taurocholic acid itself. For oral supplemental preparations derived from ox bile extract, specific taurocholic acid content per dose varies by product and is not standardized. Most clinical research has focused on mixed bile salts rather than isolated taurocholic acid, and data on its direct effects in humans remain limited. While taurocholic acid is generally recognized as safe when consumed in amounts typical of nutritional products, more robust clinical trials are needed to fully validate its efficacy and identify potential therapeutic applications.
9. Safety Considerations and Interactions
9.1 Hepatotoxicity at Pathological Concentrations
Bile acids including cholic acid, its taurine conjugate (taurocholate), and lithocholic acid cause cholestasis and hepatocellular damage when present at pathological levels. This injury is accompanied by alterations in the expression of hepatobiliary transporters.
9.2 Fetal Cardiotoxicity in Obstetric Cholestasis
Elevated taurocholic acid in the context of pregnancy-related cholestasis presents a documented and serious safety concern. The effect of the primary bile acid taurocholate (0.3 mM and 3 mM) on cultures of single cardiomyocytes was a reversible decrease in the rate of contraction and in the proportion of beating cells. Addition of taurocholate to a network of synchronously beating cells caused a similar decrease in the rate of contraction. Furthermore, the integrity of the network was destroyed, and cells ceased to beat synchronously. Taurocholate also resulted in altered calcium dynamics and loss of synchronous beating. These data suggest that raised levels of the bile acid taurocholate in the fetal serum in obstetric cholestasis may result in the development of a fetal dysrhythmia and in sudden intra-uterine death.
Obstetric cholestasis (OC) is a pregnancy-specific liver disease characterized by increased levels of bile acid and pruritus. Raised maternal bile acid levels could be associated with intrauterine death, fetal distress, and preterm labor and also alter the rate and rhythm of cardiomyocyte contraction and may cause fetal arrhythmic events.
In untreated intrahepatic cholestasis of pregnancy, fetal taurocholate concentrations positively correlated with fetal NT-proBNP, a cardiac stress biomarker (r = 0.44, p = 0.039).
Experimental research has demonstrated that the bile acid taurocholate can cause different types of dysrhythmia in individual cardiomyocytes. The changes were reversible following removal of taurocholate in adult cardiomyocytes, but not in neonatal cardiomyocytes exposed to higher concentrations (>0.3 mM).
9.3 Colorectal Cancer Promotion via Microbial Metabolism
Together, the mechanisms of microbial TCA deconjugation (yielding genotoxic H2S and tumor-promoting DCA) support a compelling link among diet, levels of TCA, the metabolic end products of TCA metabolism by intestinal bacteria, and development of CRC. While this is a public health concern at the population level related to dietary patterns rather than to supplemental use, it is a relevant safety signal for risk assessment.
Bacterial H2S production has previously been implicated as an important factor in the development of inflammatory bowel diseases such as colitis and colon cancer, an effect potentially due to its destructive influence on the mucus barrier of the colon and its genotoxicity.
9.4 Drug Interactions
Based on pharmacological class, known interactions relevant to bile acid preparations include the following:
- Bile acid sequestrants: Bile acid sequestering agents such as cholestyramine and colestipol may interfere with the action of bile acid preparations by reducing their absorption.
- Aluminum-based antacids: Aluminum-based antacids have been shown to adsorb bile acids in vitro and may be expected to interfere with bile acid preparations in the same manner as bile acid sequestering agents.
- Estrogens, oral contraceptives, and clofibrate: Estrogens, oral contraceptives, and clofibrate increase hepatic cholesterol secretion and encourage cholesterol gallstone formation, and hence may counteract the effectiveness of bile acid-based treatments.
- Antiretroviral drugs: For the closely related TUDCA, there are no known interactions between bile acids and antiretroviral drugs, based on available clinical trial documentation.
9.5 Drug Delivery Applications: Tolerability of Sodium Taurocholate
Toxicity studies of liposomes containing sodium taurocholate showed that they were well tolerated and could be used as drug delivery systems for compounds with low water solubility, in contrast to sodium deoxycholate, which showed significant toxicity on human corneal epithelial cells.
9.6 Overall Safety Profile Assessment
At physiological concentrations, taurocholic acid is an endogenous molecule that the human body continually produces and recycles. The safety concerns documented in the literature are primarily associated with pathological elevations (as in cholestatic disease states) rather than with modest supplemental exposure. However, no systematic human safety trials of exogenous taurocholic acid supplementation across a range of doses have been published. The animal acute toxicity data (median lethal dose of taurocholic acid in newborn rats: 380 mg/kg) provide some toxicological context, but extrapolation to supplemental human use requires caution.
10. Summary of Evidence Strength by Domain
- Lipid and fat-soluble vitamin absorption: Strong mechanistic and physiological evidence; foundational biochemistry with no genuine scientific controversy.
- Cholagogue/choleretic activity: Well-established pharmacological activity; historically recognized and consistent with mechanism.
- Colorectal cancer risk association (high circulating TCA): One large prospective epidemiological study plus substantial mechanistic/preclinical data; causal role not definitively established in humans.
- Gut microbiome modulation: Substantial mechanistic evidence and animal data; controlled human interventional trials specifically on TCA are ongoing but limited.
- GLP-1 secretion and metabolic effects: Preclinical (in vitro and animal) evidence only; no controlled human data.
- Hepatic lipid reduction: Animal model evidence only; no human clinical trials reported.
- Fetal cardiotoxicity in cholestasis: Strong in vitro and clinical correlational evidence; represents a documented safety concern, not a therapeutic application.
References
Go back